Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors

Osaka and Tokyo, Japan, October 1, 2009 --- Takeda Pharmaceutical Company Limited (Osaka, President: Yasuchika Hasegawa), AstraZeneca K.K. (Osaka, President and CEO: Masahiro Kato), Mitsubishi Tanabe Pharma Corporation (Osaka; President and CEO: Michihiro Tsuchiya), and Eisai Co., Ltd. (Tokyo; President and CEO: Haruo Naito) jointly announced today the submission of an application[*1] for additional indications for Helicobacter pylori (“H. pylori”) eradication by concomitant therapy with three proton pump inhibitors, lansoprazole, omeprazole, and rabeprazole sodium, marketed in Japan under four brand names. This concomitant therapy consists of a proton pump inhibitor, amoxicillin hydrate, and either clarithromycin or metronidazole and is indicated for the eradication of H. pylori in gastric MALT lymphoma[*2], the stomach after endoscopic resection of early stage gastric cancer, and idiopathic thrombocytopenic purpura[*3] (“ITP”).